-
公开(公告)号：BR0211780A
公开(公告)日：2004-07-27
申请号：BR0211780
申请日：2002-08-07
Applicant: CELLTECH R&D LTD
Inventor： DYKE HAZEL JOAN , WATSON ROBERT JOHN
IPC: A61K31/453 , A61P1/00 , A61P1/02 , A61P11/00 , A61P11/06 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/10 , A61P25/00 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/02 , A61P37/08 , A61P43/00 , C07D405/12 , C07D309/08 , A61K31/445
Abstract: Compounds of the general formula (I) are described wherein R 1 and R 2 , which may be the same or different, is each a hydrogen atom or a CF 3 , CF 2 H or CFH 2 group, provided that when one of R 1 and R 2 is a hydrogen atom, then the other is a CF 3 , CF 2 H or CFH 2 group, and the salts, solvates or hydrates thereof. Compounds of the invention are potent MMP inhibitors which advantageously do not cause tendonitis in a relevant animal model. Compounds of the invention may be expected to be of use in medicine, especially where the avoidance of side effects, such as joint pain, is desired.
-
公开(公告)号：CA2473089A1
公开(公告)日：2003-08-28
申请号：CA2473089
申请日：2003-02-19
Applicant: CELLTECH R&D LTD
IPC: A61K31/4468 , A61P1/04 , A61P11/06 , A61P17/00 , A61P19/02 , A61P25/00 , A61P27/16 , A61P29/00 , A61P31/12 , A61P33/00 , A61P37/02 , A61P37/06 , C07D211/58 , C07D401/12 , C07D405/12 , C07D409/12 , A61K31/17 , C07C275/28 , A61K31/453 , A61K31/4535 , A61K31/4709
Abstract: Cyclic amino derivatives of formula (1) are described: (1) wherein: m and n, which may be the same or different, is each zero or the integer 1 or 2; AIk3 ~ is a covalent bond or a straight or branched C~1-6 alkylene chain; R1~ and R2~, which may be the same or different, is each a hydrogen atom or a straig ht or branched C~1-6 alkyl group; D is an optionally substituted aromatic or heteroaromatic group; E is an optionally substituted C~7-10 cycloalkyl, C~7- 10 cycloalkenyl or C~7-10 polycycloaliphatic group; and the salts, solvates, hydrates, tautomers or N-oxides thereof. The compounds are potent and selective modulators of the interaction between CXCR3 and its chemokine ligands and are thus of use in medicine, for example in the prevention or treatment of conditions involving inappropriate T-cell trafficking such as certain inflammatory, autoimmune and immunoregulatory disorders as described hereinafter.
-
公开(公告)号：DE602004003256T2
公开(公告)日：2007-05-03
申请号：DE602004003256
申请日：2004-06-18
Applicant: CELLTECH R&D LTD
Inventor： OWEN DAVID ALAN , WATSON ROBERT JOHN , ALLEN DANIEL REES , SHARPE ANDREW , DYKE HAZEL JOAN
IPC: C07D211/96 , A61K31/451 , A61P37/00
-
公开(公告)号：AT345328T
公开(公告)日：2006-12-15
申请号：AT04742999
申请日：2004-06-18
Applicant: CELLTECH R&D LTD
Inventor： OWEN DAVID ALAN , WATSON ROBERT JOHN , ALLEN DANIEL REES , SHARPE ANDREW , DYKE HAZEL JOAN
IPC: A61P37/00 , C07D211/96 , A61K31/451
-
公开(公告)号：CA2526880A1
公开(公告)日：2004-11-04
申请号：CA2526880
申请日：2004-04-08
Applicant: CELLTECH R&D LTD
Inventor： MEISSNER JOHANNES WILHELM GEOR , WATSON ROBERT JOHN , OWEN DAVID ALAN
IPC: C07D211/58 , A61K31/452 , A61P37/02 , A61P37/08 , C07D409/12
Abstract: Compounds of formula (1) wherein,m,n,R1,R2,Ra,ALK3, E and Y are as defined i n the claims, being potent and selective inhibitors of chemokine binding to th e CXCR3 receptor, are accordingly of use in the treatment and/or prevention of conditions involving inappropriate T-cell trafficking, including inflammator y, autoimmune and immurforegulatory disorders such as rheumatoid arthritis.
-
Patent Agency Ranking
公开(公告)号：CA2456291A1
公开(公告)日：2003-02-20
申请号：CA2456291
申请日：2002-08-07
Applicant: CELLTECH R&D LTD
Inventor： DYKE HAZEL JOAN , WATSON ROBERT JOHN
IPC: A61K31/453 , A61P1/00 , A61P1/02 , A61P11/00 , A61P11/06 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/10 , A61P25/00 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/02 , A61P37/08 , A61P43/00 , C07D405/12 , C07D309/08 , A61K31/445
Abstract: A compound of formula (I) wherein : R1 and R2, which may be the same or different, is each a hydrogen atom or a CF3, CF2H or CFH2 group, provided th at when one of R1 or R2 is a hydrogen atom the other is a CF3, CF2H or CFH2 gro up ; and the salts, solvates or hydrates thereof. The compounds are potent MMP inhibitors which advantageously do not cause tendonitis in a relevant animal model. The compounds may be expected to be of use in medicine, especially where the avoidance of side effects such as joint pain is desired.
-
公开(公告)号：PL368228A1
公开(公告)日：2005-03-21
申请号：PL36822802
申请日：2002-08-07
Applicant: CELLTECH R&D LTD
Inventor： DYKE HAZEL JOAN , WATSON ROBERT JOHN
IPC: A61K31/453 , A61P1/00 , A61P1/02 , A61P11/00 , A61P11/06 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/10 , A61P25/00 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/02 , A61P37/08 , A61P43/00 , C07D405/12 , C07D309/08 , A61K31/445
Abstract: Compounds of the general formula (I) are described wherein R 1 and R 2 , which may be the same or different, is each a hydrogen atom or a CF 3 , CF 2 H or CFH 2 group, provided that when one of R 1 and R 2 is a hydrogen atom, then the other is a CF 3 , CF 2 H or CFH 2 group, and the salts, solvates or hydrates thereof. Compounds of the invention are potent MMP inhibitors which advantageously do not cause tendonitis in a relevant animal model. Compounds of the invention may be expected to be of use in medicine, especially where the avoidance of side effects, such as joint pain, is desired.
-
公开(公告)号：ZA200401873B
公开(公告)日：2005-03-08
申请号：ZA200401873
申请日：2004-03-08
Applicant: CELLTECH R&D LTD
Inventor： JOAN DYKE HAZEL , WATSON ROBERT JOHN
IPC: A61K31/453 , A61P1/00 , A61P1/02 , A61P11/00 , A61P11/06 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/10 , A61P25/00 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/02 , A61P37/08 , A61P43/00 , C07D405/12 , C07D , A61K , A61P
Abstract: Compounds of the general formula (I) are described wherein R 1 and R 2 , which may be the same or different, is each a hydrogen atom or a CF 3 , CF 2 H or CFH 2 group, provided that when one of R 1 and R 2 is a hydrogen atom, then the other is a CF 3 , CF 2 H or CFH 2 group, and the salts, solvates or hydrates thereof. Compounds of the invention are potent MMP inhibitors which advantageously do not cause tendonitis in a relevant animal model. Compounds of the invention may be expected to be of use in medicine, especially where the avoidance of side effects, such as joint pain, is desired.
-
公开(公告)号：CA2528317A1
公开(公告)日：2004-12-29
申请号：CA2528317
申请日：2004-06-18
Applicant: CELLTECH R&D LTD
Inventor： WATSON ROBERT JOHN , SHARPE ANDREW , ALLEN DANIEL REES , OWEN DAVID ALAN , DYKE HAZEL JOAN
IPC: C07D295/22 , A61K31/496 , A61P37/08 , C07D211/56 , C07D295/26 , C07D309/14
Abstract: A class of piperazine and related heterocyclic derivatives, substituted at t he 4-position by a substituted aryl or heteroaryl moiety, and at the 1-position by an ethylsulfonyl group which in turn is substituted at the 2-position by a hydroxamic acid moiety and also by a range of alternative substituents, bein g potent inhibitors of CD23 shedding, are useful in the treatment and/or prevention of allergic, inflammatory and neoplastic diseases.
-
公开(公告)号：AU2003208423A1
公开(公告)日：2003-09-09
申请号：AU2003208423
申请日：2003-02-19
Applicant: CELLTECH R&D LTD
IPC: A61K31/4468 , A61P1/04 , A61P11/06 , A61P17/00 , A61P19/02 , A61P25/00 , A61P27/16 , A61P29/00 , A61P31/12 , A61P33/00 , A61P37/02 , A61P37/06 , C07D211/58 , C07D401/12 , C07D405/12 , C07D409/12 , A61K31/453 , A61K31/4535 , A61K31/4709 , A61K31/17 , C07C275/28
Abstract: Cyclic amino derivatives of formula (1) are described: (1) wherein: m and n, which may be the same or different, is each zero or the integer 1 or 2; Alk 3 is a covalent bond or a straight or branched C 1-6 alkylene chain; R 1 and R 2 , which may be the same or different, is each a hydrogen atom or a straight or branched C 1-6 alkyl group; D is an optionally substituted aromatic or heteroaromatic group; E is an optionally substituted C 7-10 cycloalkyl, C 7-10 cycloalkenyl or C 7-10 polycycloaliphatic group; and the salts, solvates, hydrates, tautomers or N-oxides thereof. The compounds are potent and selective modulators of the interaction between CXCR3 and its chemokine ligands and are thus of use in medicine, for example in the prevention or treatment of conditions involving inappropriate T-cell trafficking such as certain inflammatory, autoimmune and immunoregulatory disorders as described hereinafter.
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.025 seconds)
